Mitochon Pharma - About the company
Mitochon Pharma is a seed company based in Radnor (United States), founded in 2014 by John Geisler and Robert Alonso. It operates as a Biotech pioneering mitochondrial-targeted therapies for neurodegenerative and neuromuscular diseases. Mitochon Pharma has raised $2.02M in funding from Ben Franklin Technology Partners. The company has 449 active competitors, including 155 funded and 82 that have exited. Its top competitors include companies like Alector, Juvenescence and Annexon.
Company Details
Biotech pioneering mitochondrial-targeted therapies for neurodegenerative and neuromuscular diseases. The company focuses on developing drugs that target the mitochondria to treat serious diseases with unmet medical needs. Their development programs primarily target time-sensitive insidious neurodegenerative and neuromuscular diseases. By correcting mitochondrial dysfunctions, they aim to open the door for a broad range of disease-modifying therapies. Their approach lies in modulating mitochondria function, resulting in cellular effects that promote survival, lower cell damage, increase cellular repair, improve cellular function and biomarkers, and reduce disease state. They are bringing forward a unique platform to treat a host of diseases, working upstream at the root of disease progression. This is a clinical-stage company.
Key Metrics
Founded Year
2014
Location
Radnor, United States
Stage
Seed
Total Funding
$2.02M in 4 rounds
Latest Funding Round
Investors
Ranked
190th among 449 active competitors
Employee Count
2 as on Dec 31, 2021
Sign up to download Mitochon Pharma's company profile
Mitochon Pharma's funding and investors
Mitochon Pharma has raised a total funding of $2.02M over 4 rounds. Its first funding round was on Apr 29, 2016. Its latest funding round was a Grant (prize money) round on Sep 28, 2021 for $*****. 1 investor participated in its latest round. Mitochon Pharma has 3 institutional investors.
Here is the list of recent funding rounds of Mitochon Pharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 28, 2021 | 5823591 | Grant (prize money) | 3188568 | 3649103 | 6096619 | 3339374 |
Oct 03, 2017 | 4067285 | Grant (prize money) | 2745243 | 6457376 | 4195581 | |
May 17, 2016 | 6846014 | Seed | 9556980 | 1000780 | 8354358 |
Access funding benchmarks and valuations. Sign up today!View details of Mitochon Pharma's funding rounds and investors
Mitochon Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Mitochon Pharma are John Geisler and Robert Alonso.
Here are the details of Mitochon Pharma's key team members:
- John Geisler: Founder & CSO of Mitochon Pharma.
- Robert Alonso: Chief Executive Officer and Founder of Mitochon Pharma.
View details of Mitochon Pharma's Founder profiles and Board Members
Mitochon Pharma's employee count trend
Mitochon Pharma has 2 employees as of Dec 21. The total employee count is the same as what it was in Dec 20. Here is Mitochon Pharma's employee count trend over the years:
Uncover Mitochon Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Mitochon Pharma's Competitors and alternates
Top competitors of Mitochon Pharma include Alector, Juvenescence and Annexon. Here is the list of Top 10 competitors of Mitochon Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 72/100 | |
2nd |  Juvenescence 2017, Dublin (Ireland), Series B | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | $290M | 68/100 | |
3rd | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
4th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
5th | Axsome Therapeutics 2012, New York City (United States), Public | Developer of therapeutic solutions for the management of CNS disorders | $8.7M | 65/100 | |
6th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response | $192M | 63/100 | |
7th | US World Meds 2001, Louisville (United States), Series B | Developer of therapeutics for the treatment of multiple diseases | $149M | 63/100 | |
8th | Cognition Therapeutics 2007, Pittsburgh (United States), Public | Developer of small molecule drugs for neurodegenerative diseases | $36.1M | 63/100 | |
9th | Blue Rock Therapeutics 2016, Boston (United States), Acquired | Stem cell therapies for cardiovascular and neurological diseases | $225M | 62/100 | |
10th |  Atalanta Therapeutics 2019, Boston (United States), Series B | Developer of RNAi therapeutics to treat neurodegenerative diseases | $262M | 62/100 | |
190th | Mitochon Pharma 2014, Radnor (United States), Seed | Biotech pioneering mitochondrial-targeted therapies for neurodegenerative and neuromuscular diseases | $2.02M | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Mitochon Pharma's competitors? Click here to see the top ones
Mitochon Pharma's Investments and acquisitions
Mitochon Pharma has made no investments or acquisitions yet.
News related to Mitochon Pharma
•
EMA approves Mitochon’s neurogenerative disease studyPharmaceutical Technology•Jan 10, 2024•Mitochon Pharma
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Mitochon Pharma
Explore our recently published companies
- CiaoDott - Turin based, 2025 founded, Seed company
- Native - Seattle based, 2024 founded, Series A company
- Atom Insights - Montreal based, 2025 founded, Acquired company
- EntryTicket - India based, 2024 founded, Unfunded company
- Jagannath Gangaram Pednekar Jewellers - Mumbai based, 1950 founded, Unfunded company
- Rodeo - New York City based, 2023 founded, Seed company
